Impact of anti-androgen therapies on COVID-19 susceptibility: a case-control study in male population from two COVID-19 regional centers of Lombardy (Italy)
Lazzeri et al.,
Impact of anti-androgen therapies on COVID-19 susceptibility: a case-control study in male population from two..,
medRxiv, doi:10.1101/2020.04.20.20068056 (Preprint)
Retrospective case-control study in Italy with 943 male COVID-19 patients, 45 on chronic 5ARI treatment (finasteride/dutasteride). There was significantly fewer COVID-19 patients >55 on 5ARI treatment compared to age-matched controls (5.57 vs. 8.14%, p=0.0083). The difference was greater for men aged >65 (7.14 vs. 12.31%, p=0.0001). There was no significant difference for ICU admission or death.
risk of death/ICU, 23.0% higher, OR 1.23, p = 0.33, multivariable, RR approximated with OR.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Lazzeri et al., 21 Sep 2020, retrospective, Italy, preprint, 11 authors.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.04.20.20068056; this version posted September 21, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Impact of anti-androgen therapies on COVID-19 susceptibility: a case-control study in
male population from two COVID-19 regional centers of Lombardy (Italy)
Massimo Lazzeri, MD-PhD1*, Stefano Duga, PhD1,2*, Elena Azzolini, MD1, Vittorio Fasulo,
MD1, Nicolò Buffi, MD1-2, Alberto Saita, MD1, The Humanitas COVID-19 Task Force1, The
Humanitas Gavazzeni COVID-19 Task Force3, Rodolfo Hurle, MD1, Alessandro Nobili, MD4,
Maurizio Cecconi, MD-PhD1,2, Paolo Casale, MD1, Rosanna Asselta, PhD1,2
1
Humanitas Clinical and Research Center – IRCCS –, via Manzoni 56, 20089 Rozzano (Mi) –
Italy
2
Humanitas University, Department of Biomedical Sciences, Via Rita Levi Montalcini 4,
20090 Pieve Emanuele – Milan, Italy
3
Humanitas Gavazzeni-Castelli, Bergamo, Italy
4
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri, 2 , 20156, Milan
*Equally contributed
Short title: 5ARIs and the risk of COVID-19
Keywords: COVID-19, 5-alpha reductase inhibitors, androgens, sex.
Manuscript word count: 1200
Corresponding Authors:
Massimo Lazzeri, MD, PhD
Department of Urology
Istituto Clinico Humanitas IRCCS
Via Manzoni 56 (20089) Rozzano – Milan (Italy)
Email: massimo.lazzeri@humanitas.it
Stefano Duga, PhD
Department of Biological Sciences
Humanitas University
Via Rita Levi Montalcini 4 (20090) Pieve Emanuele - Milan (Italy)
Email: stefano.duga@hunimed.eu
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
medRxiv preprint doi: https://doi.org/10.1101/2020.04.20.20068056; this version posted September 21, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
KEY POINTS
Question: May treatment of benign prostatic hyperplasia with 5-alpha reductase inhibitors
(5ARIs) impact on COVID-19-related hospitalization risk?
Findings: In this case-control study, which compared 943 adult males hospitalized for
COVID-19 with age-matched men from Lombardy (all beneficiaries of the Regional Health
Service), the proportion of patients aged >55 years, who were exposed to 5ARIs (dutasteride,
finasteride), was significantly lower (5.57%) than that of the general male population (8.14%)
(p=0.0083, 95%CI=0.75-3.97%).
Meaning: The use of 5ARIs was associated with a potential reduced risk of hospitalization for
COVID-19 in men older than >55 years. This suggests the opportunity to test whether antiandrogen therapies can prevent the transition from paucisymptomatic SARS-CoV-2 infection
to overt pulmonary disease.
medRxiv preprint doi: https://doi.org/10.1101/2020.04.20.20068056; this version posted September 21, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
ABSTRACT
Importance: There are gender differences in vulnerability to the Coronavirus..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit